ãã¡ãã¯äŒå¡éå®ãšãªã£ãŠãããŸãã
ãã°ã€ã³ããŠçãµã€ã®å
šãŠã®æ©èœã䜿ã
â SNSã§ãã°ã€ã³
äžèšSNSã¢ã«ãŠã³ãããæã¡ã®æ¹ã¯ãã¡ãŒã«ã¢ãã¬ã¹ã®å
¥åäžèŠã§ç°¡åç»é²
â ã¡ãŒã«ã¢ãã¬ã¹ã§ãã°ã€ã³
ã¢ã«ãŠã³ãããæã¡ã§ãªãæ¹ã¯ãã¡ã
â ãå°æ³çŽäžéãšæ¥æ¬ã®ç
çããè€åèïŒèïŒïŒå
æ瀟ããŒããŒããã¯ã¹ 2005/10/21
å°æ³ã®çªèšè
ãã¡ããæããèªåã®è³ãçã£ããšããçºèšã¯ãäŸãã°ä»¥äžã®ãããªãã®ã§ããã
ããé³¥ã¯ããããªããã©ãããŠã§ããïŒãç·çãããã€ã§ãã€ã¬ãããã ã
ãããã¯ãïŒïŒïŒïŒå¹Žã®å€ãèªæ°å
å
ã§éµæ¿æ°å¶åãããã£ãŠãæ¿ããæ»é²ãããè¿ãããŠãããšãã®ããšã ãšãããããã«ãå°æ³ã¯ãç·çããã£ãŠãããšæºãŸããã ããã¢ã¬ããããšãããç²ããã©ããããã§ãä»æ¥ã¯ãã³ãã³ã ãããã³ãã³ïŒããæè¿ãŸãæç«ã¡ãããã ãããªã¬æè¿ã倢粟ãã¡ãããã ããããããããããçžåœæ¿ããã ããªããä»æ¥ãããã°ããã¯å³æãæ人ã ãªããªã©ãšåœŒãã«åãã£ãŠèšããïŒäººã§ãã€ãã€ããããšããããšãããã ãããçªèšè
ã¯å°æ³ãå¯ãã«ããšãéçããªã©ãšåŒãã§ããããå±±æïŒå±±åŽæïŒãšè©±ãåãããã ããšçŽåŸããŠãããšãã話ãé±åèªãæžããŠããã
- [å¿åãã]
é»ç£æ³¢å
µåšã®è¢«å®³ãåããŠããæ¹ãž
岩åœèªç©ºèªè¡éãžå©ããæ±ããŠäžããã
- [å¿åãã]
>>354
â å
ïŒïŒ©ïŒè«å ±éšå¡ãïœ.ïœïœïœïœïœ
ãïœïœïœïœ
ïœã®èªãé»ç£æ³¢å
µåšâ
âããªãŒã»ãã©ãŠã¢ãŒããããã¯ã€ããžãããããã€ã³ã¿ãã¥ãŒã®æéãé ããŠå
æ ã§ããæã
ã¯ããªããå°æ¬ããŠããŸããã©ãŒãã³ã°ãæºåž¯é»è©±æè¡ã®ç倧ãªå±éºæ§ã«å¯ŸããŠçºãããããã®åæ°ããã¡ãã»ãŒãžã«ããªãã®èœåãšä»æ¥æã€ç¥èãç解ããããã«ç°¡åãªå±¥æŽã«ã€ããŠãèããããã®ã§ããã
- [å¿åãã]
>>356
ãããïŒïŒïŒïŒå¹Žã«ç§ã¯è»ã§ãã€ã¯ãæ³¢æŠã®ããããé¢ã«é¢ããå§ããŸãããã€ã®ãªã¹ã§ãã§ãããã€ã¯ãæ³¢æŠäºã®å
šåŽé¢ãããã人äœã«äžããå±éºæ§ãããã¡ããã¬ãŒããŒãè»äºäœ¿çšã«ã€ããŠåŠã³ãŸããããã®åŸãïŒïŒå¹Žéã®ä»äºã®äžéšã§ãããå·æŠæ代ã®ãã€ã¯ãæ³¢ã¯ä»ãšåæ§ãç§å¯æŠåšãšããŠäœ¿ããããããã¯å®ç§ãªæŠåšã§ããã人ã
ã¯èªåãæ»æãããŠãããšæ°ä»ããªãã§ããããã©ã®æ¿åºã«ãå人ãéå£ã«å¯Ÿããæ»æãå¯èœã§å®è¡ãããŠãããéã«ãã矀è¡ã«å¯ŸããŠãåæ§ã§ïŒïŒã«æããïŒå¹ŽåãäœåŒ·åºŠã®æ»æã§ç倧ãªç¥çµçãã¡ãŒãžã身äœçãã¡ãŒãžãã¬ã³ãåŒãèµ·ããããšãã§ããŸããæèã®æ¹å€ãã§ããŸãã
- [å¿åãã]
æé·ã®å®¶ãšçµ±äžæäŒãäž»ç¯ã§ã
YouTubeã§æé·ã®å®¶ã§æ€çŽ¢ããŠãã ãã
å©æš©ã¯å²ããããã
éå£ã¹ããŒã«ãŒã¯ããžãã¹
- [å¿åãã]
ããã
ãã®æ ¹æ ãåãããªãã
- [å¿åãã]
>>355
ããã¯å
šç¶éããšæãã
ã©ãããŠèªç©ºèªè¡éãªãã ïŒ
- [å¿åãã]
ããããªç®çã®å·¥äœããã£ãŠãããããªäººãããããªè¢«å®³ãåããŠãããã ãã
ããããªç
æ°ãå··ã®ãã¥ãŒã¹ã«ãªããã®ããªããªããããªãã®ãééãä»ã®åå ã§èµ·ãã£ãŠããšæãããŸããŠãäºçŽ°ãªãã©ãã«ãå§å©ãšãæ¥æ¬äžã§æ¥ã
èµ·ãã£ãŠããã
éå£ã¹ããŒã«ãŒãšããã®ã¯çžæã«æ°ã¥ãããç®çã§è¡ããããã®ã被害ãèªèŠããŠããã®ãå 害è¡çºãšããŠèšã£ãŠããã ãã§ãæ°ã¥ããªãããã«è¡ãããããããªé»ç£æ³¢ãã¯ãããžãŒã»éå£ã¹ããŒã«ãŒå·¥äœã¯ã¯ããã«å€ããã
被害è
ãæ°å人ãšããåœè¢«å®³è
ãæ¬åœã®è¢«å®³è
ãã¯ããŠããããããªãã®æ°·å±±ã®äžè§ã ãã
- [å¿åãã]
â NALTREXONE ATTENUATES THE ANTIPARKINSONIAN EFFECTS OF PICOTESLA RANGE MAGNETIC FIELDS
ãã³ãã¹ã©ç¯å²ã®ç£çã®åããŒãã³ãœã³ç
å¹æã匱ãããã«ãã¬ããœã³
REUVEN SANDYK and ROBERT P.IACONO / Intern. J. Neuroscience, 1994,Vol.78,pp.111-122
ãã³ãã¹ã©ç¯å²ã®ç£å ŽïŒMFïŒã«ããé èå€æ²»çã¯ãããŒãã³ãœã³ç
çç¶ã®ç®¡çã«ãããŠå¹æçãªæ²»çæ³ã瀺ãããŠããŸãããã®ãããªéåžžã«åŒ±ãç£å ŽãããŒãã³ãœã³ç
ã®çç¶ãæ¹åããä»çµã¿ã¯ç¥ãããŠããŸãããæŸæäœã¯ãç£æ°æç¥åšããšããŠæ©èœããããšã瀺ãããŠãããããŸããŸãªåŒ·åºŠã®ç£å Žã«æé²ããããšã¡ã©ããã³ã®åæ³ã劚害ããããããããŒãã³ãœã³ç
çç¶ã«ãããç£çã®æçãªå¹æã¯æŸæäœã®ã¡ã©ããã³ã®äœçšãéããŠéšåçã«åªä»ãããããšãææ¡ãããŠããŸããåç©ç 究ã¯ãå€éšããé©çšãããç£å ŽããããŒãã³ãœã³ç
çç¶ãå«ãåºç¯ãªç
çç¶æ
ã«é¢ä¿ããŠãããªããªã€ãããããã®æŽ»æ§ã«ã圱é¿ãäžããããšã瀺ããŠããŸãã
- [å¿åãã]
>>362
ããŒãã³ãœã³ç
çç¶ã«ãããç£å Žã®æçãªå¹æãããªããªã€ãç³»ã®åªä»ã«é¢ä¿ãããã©ããã調ã¹ãããã«ãå»çè¡çºèª¬æã®åŸã«ãããŒãã³ãœã³ç
æ£è
ãç£å Žã®é©çšã«ããçç¶ã®æ¹åã瀺ããåŸã«æã
ã¯ãªããšãŒãå容äœæ®æè¬ãã«ãã¬ããœã³(50mg, P.O.)ãããŒãã³ãœã³ç
æ£è
ã«æäžããŸãããè©Šçšã®çµæã¯ããã«ãã¬ããœã³ãç£çã®æããŒãã³ãœã³ç
å¹æãéšåçã«é転ããããããã£ãŠãªããªã€ããããããããŒãã³ãœã³ç
çç¶å
ã®ãããã®æ¥µããŠåŒ±ãç£å Žã®èšåºå¹æã®åªä»ã®é¢äžã瀺ããŸããããããã®çµæã¯ããã³ãã¹ã©ç¯å²ã®ç£å Žã®æããŒãã³ãœã³ç
å¹æãå®å
šã«çºçŸãããã«ã¯ãç¡å·ã®ãªããªã€ãã·ã¹ãã ãå¿
èŠã§ããããšã瀺åããŠããŸãã
- [å¿åãã]
>>363
ãã³ãã¹ã©ç¯å²ç£å ŽïŒMFïŒã«ããé èå€æ²»çã¯ãã¬ãããèªçºæ§ãžã¹ãããžã¢ãçºçããŠãããããã®æ£è
ãå«ããããŒãã³ãœã³ç
çç¶ã®ç®¡çã«ãããå¹æçã§å®å
šãã€é©æ°çãªæ§åŒãšããŠæè¿å ±åãããŠããŸãïŒSandyk, 1992 a; b; c; Sandyk et al, 1992; SandykïŒDerpapas, 1993 a; b; SandykïŒIacono, 1993; SandykïŒDerpapas, å°å·äžaïŒããã ãããã®ãããªéåžžã«åŒ±ãç£å ŽãããŒãã³ãœã³ç
ã®çç¶ãæ¹åããä»çµã¿ã¯äžæã®ãŸãŸã§ããç£å Žã«æŽé²ãããçç©ã®æãåçãªåå¿ã®1ã€ã¯ãæŸæäœãšã¡ã©ããã³ã®åæ³ã«ããã圱é¿ãå«ã¿ãŸã(Semm, 1983; Welker et al, 1983; Wilson et al, 1981; Cremer-Bartels et al, 1983; Olcese et al, 1985; Rudolph et al, 1988; Moore-Ede et al, 1992)ã
- [å¿åãã]
>>364
çŸåšãæŸæäœã¯ãç£æ°æç¥åšãã§ããããšãèªèãããŠãã(Semm et al, 1980; Semm, 1983; Cremer-Bartels et al, 1983; DemaineïŒSemm, 1985; Olcese et al, 1985; 1988; Semm, 1992)ããããŠããŸããŸãªåŒ·åºŠã®ç£å Žãžã®æŽé²ã¯ãå®éšåç©ãšäººéã®äž¡æ¹ã§ã¡ã©ããã³åæ³ãæ¥éã«æå¶ããããšãæããã«ããŸãã(Wilson et al, 1981; 1986; Cremer-Bartels et al, 1983; OlceseïŒReuss, 1986; Rudolph et al, 1988; Semm, 1992)ãã©ããã§ã¯ãå€éã®å°ç£æ°ã®æ°Žå¹³æåã®å転ããè¡æŒ¿ã¡ã©ããã³ã¬ãã«ãçŽ2æéæå¶ããããŸãŸã«ãã15å以å
ã«ã¡ã©ããã³åæ³ãæå¶ããããšãå ±åãããŠããŸã(Welker et al, 1983)ãããã§ã¯ãå€éã«ç£å Žã«30åéæŽé²ãããšã60ïŒ
ã®è¢«éšè
å
ã§è¡æŒ¿ã¡ã©ããã³æ¿åºŠã70ïŒ
æå¶ãããããšãå ±åãããŠããŸã(Semm, 1992)ã
- [å¿åãã]
>>365
ã¡ã©ããã³ãšãã®å容äœã¯ãç·æ¡äœã網ç¶äœåœ¢æãªã©ã®çŸæ£ã®ç
æ
ççã«é¢äžããè³é åå
ã§å®èšŒãããŠãããããæŸæäœã«ããã
ç£å Žã®åœ±é¿ã¯ããŒãã³ãœã³ç
çç¶ã«é¢é£ããŠããŸã(Niles et al, 1973; Cardinali et al, 1979; VacasïŒCardinali, 1979;
Sallanon et al, 1982; Laudon et al, 1988)ãããã«ãã¡ã©ããã³ã¯äžè³ããã³èŸºçžç³»ã®ããŒããã³äœåæ§æŽ»æ§ã調ç¯ãïŒCotzias
et al, 1971; Bradbury et al, 1985; GafforiïŒVan Ree, 1985; SandykïŒFisher, 1989 a; Burton et al, 1991)ããã€ãããããŒ
ããã³äœåæ§æ©èœãé»å®³ãã(Cotzias et al, 1971; ZisapelïŒLaudon, 1983; Zisapel et al, 1982; 1983; Burton et al, 1991)
ããšãå®éšçç 究ã«ããæããã«ãããŠããŸãã
- [å¿åãã]
>>366
ç·æ¡äœããã³äžè³èŸºçžç³»ã®ããŒããã³äœåæ§æŽ»åã®å¢åŒ·ã«è³ããããŒããã³æŸåºãè±æå¶ã§ãããç£çã«ããã¡ã©ããã³åæ³ã®æ¥éãª
æå¶ã¯ããããã£ãŠãããŒãã³ãœã³ç
çç¶ã®æ¹åãéšåçã«èª¬æãããšä»®å®ãããŠããŸã(Sandyk, 1992 a)ãããã«ãã¡ã©ããã³ã¯
ã»ãããã³(5-HT)æ®æè¬ãšããŠäœçšãããã(SmytheïŒLazarus, 1974 a; b; Rozencwaig et al, 1987)ãç£å Žã«ããã¡ã©ããã³ã®é»å®³
ã¯ã»ãããã³(5-HT)ã®æ©èœã®å¢åŒ·ã«ã€ãªããããã®æ¬ ä¹ãããŒãã³ãœã³ç
æ§ã®éåçç¶ããã³æ
åçç¶ã®ç
æ
ççã«ãé¢ä¿ããŸã
(Dray, 1981; Mayeux et al, 1984; SandykïŒFisher, 1988; McCance-Katz et al, 1992)ã
- [å¿åãã]
>>367
è¿å¹Žãå
å æ§ãªããªã€ãããããã¯ãå€éšããå ãããã人工ç£æ°åºæ¿ããã³å°ç£æ°ã®å€åã«åœ±é¿ãåãããšãã蚌æ ãèç©ãã
ãŠããŸã(Ossenkopp et al, 1983; KavaliersïŒOssenkopp, 1985; 1986 a; b; KavaliersïŒOssenkopp, 1987 ; OssenkoppïŒ
Kavaliers, 1987; 1988; KavaliersïŒOssenkopp, 1992)ã匷ã倪éœæŽ»åããçããèªç¶ã®å°ç£æ°æŸä¹±ã¯ãããŠã¹ã®å€è¡æ§ã¢ã«ããèªçº
æ§é®çã軜æžããããšãå ±åãããŠããŸã(Ossenkopp et al, 1983; KavaliersïŒOssenkopp, 1984)ãå€éšããé©çšããã匱ãå転ç£å Ž
ã¯ãã¢ã«ããã®æ¥å
é®çå¹æãäœäžãã(KavaliersïŒOssenkopp, 1985)ãã¢ã«ããã®éåå¹æã匱ã(KavaliersïŒOssenkopp, 1985;
KavaliersïŒOssenkopp, 1986 a)ãã¢ã«ããèªçºæ§é®çã«å¯Ÿããèæ§çºçŸçãå€æŽã(KavaliersïŒOssenkopp, 1985)ãããŠã¹ã®ã¹ãã¬
ã¹èªçºæ§é®çã軜æžããããšãå®èšŒãããŠããŸã(KavaliersïŒOssenkopp, 1986 c)ã
- [å¿åãã]
ãããã¯ãããžãŒç¯çœªå·¥äœã§ãããªãã
å·¥åŠéšã®ææã«ãã¯ãããžãŒç¯çœªã®ã¬ã¹ãèŠããã
ç¬ããããããããªèåç¡çšœã®ãã®ãåã¯å€æåºæ¥ãªãããã
ããèšãããŸãã
- [å¿åãã]
ãããããåŒããããŠäººéãç°å¢ããªã«ã·ã¯
ãªã£ãŠããŠãããããå±ãªãã
- [å¿åãã]
>>369
èåç¡çšœãªã®ã¯é»ç£æ³¢ç¯çœªã¯ç¡ããšãé»ç£æ³¢ç¯çœªã§ç²Ÿç¥ç
ãèµ·ãããªããšããããããé»ç£æ³¢ã¯çäœã«åœ±é¿ããªããšãèšã匵ãã¡ãã£ã¢ãšåå£ãªå·¥äœå¡ãšåŸ¡çšåŠè
ã§ããšèšã£ãŠãããŠãã ããã
ã¡ãã£ã¢ããããã§è¯å®ããããã®ãªããå³åº§ã«è¿œè·¡ãããŠå«ãããé£ãããã ãããæå£ã«ç«ã€äººéã«é»ç£æ³¢ç¯çœªãè¯å®ãããªããŠã§ããããããªãã
- [å¿åãã]
- ãã®æçš¿ã¯åé€ãããŸãã
ããããã😳
- [å¿åãã]
>>368
â NALTREXONE ATTENUATES THE ANTIPARKINSONIAN EFFECTS OF PICOTESLA RANGE MAGNETIC FIELDS
ãã³ãã¹ã©ç¯å²ã®ç£çã®åããŒãã³ãœã³ç
å¹æã匱ãããã«ãã¬ããœã³
REUVEN SANDYK and ROBERT P.IACONO / Intern. J. Neuroscience, 1994,Vol.78,pp.111-122
ããã«ã0.5 Hzã®å転ç£å Žãžã®æé²ã¯ããã¥ãŒããã³ã«ãããªããšãŒãå容äœã¢ãŽãã¹ãã®æŒéã®é®çå¹æã倧å¹
ã«æžè¡°ãããŸãã
ãã匱ãç£æ°åºæ¿ãããŸããŸãªãªããªã€ãç³»ã«ææãã€ç¹ç°çãªé»å®³äœçšãæããããšã瀺åãããã·ã°ããªããšãŒãå容äœã«ããã
å¹æã¯ãããŸããã§ãã(KavaliersïŒOssenkopp, 1986 b)ãããã«ãç£æ°å
±é³Žç»åæ³(MRI)åŠçœ®ãžã®æé²ããã¢ã«ãã泚å°ãåããããŠ
ã¹ã®æŒéããã³å€éã®é®çåå¿ã®æå¶ããããããããšãå ±åãããŠããŸã(Ossenkopp et al, 1985)ãåŸã£ãŠããšããªã€ãããããã¯
ãç£çãé®çãéå掻æ§ã®èª¿ç¯ãæ°åãšè¡åã®æ¹å€ãäœæž©èª¿ç¯ãæé£è¡åãšãã£ãå€æ§ãªè¡åçãã€ççåŠçãªå¹æãçºæ®ããæ©æ§
(For review see Kavaliers & Ossenkopp, 1992)ã®äžå¯æ¬ ãªéšåãšãªãããšãã§ããšèããããŸã(Akil et al, 1984)ã
- [å¿åãã]
>>374
ç£å Žããªããªã€ãç³»ã®æŽ»æ§ã«åœ±é¿ãåãŒãä»çµã¿ã¯å®å
šã«ã¯ç解ãããŠããŸãããã«ã«ã·ãŠã ãã¬ãŒãå€ïŒæ°Žæº¶æ¶²äžã§ã«ã«ã·ãŠã ã€
ãªã³(Ca2+)ãžéžæçã«çµåãããã®æŽ»æ§ãæ¶å€±ãããééå±ãªã¬ã³ãååã®ããšãCa2+ã¯çŽ°èå
ã·ã°ãã«äŒéãæ
ã代衚çãªã»ã«ã³ã
ã¡ãã»ã³ãžã£ãŒã§ãããç¥çµçŽ°èã®ååãçªèµ·ã®äŒžå±ãç¥çµäŒéç©è³ªæŸåºãã·ããã¹å¯å¡æ§ãç¥çµçŽ°èæ»ãªã©ããŸããŸãªçŽ°èæ©èœã«
é¢äžããŠããïŒãšã€ãªããã©ã¢ïŒçäœèã«ãããŠãç¹å®ã®ã€ãªã³ã®ééæ§ãå¢å ãããèœåãæã€è溶æ§ååã®ç·ç§°ïŒã䜿çšããç 究
ã®çµæã¯ããªããªã€ãç³»ã«å¯Ÿããç£å Žã®å¹æã®å°ãªããšãããã€ãããã«ã«ã·ãŠã ããã³ä»ã®äºäŸ¡ã€ãªã³ã«å¯Ÿããäœçšãšäºææ§ããã
ããšã瀺åããŠããŸã(KavaliersïŒOssenkopp, 1986 a)ãå
·äœçã«ã¯ãã«ã«ã·ãŠã ãã¬ãŒãå€ã§ããEGTAïŒã°ãªã³ãŒã«ãšãŒãã«ãžã¢ã
ã³åé
¢é
žïŒäºäŸ¡ããã³äžäŸ¡ã®éå±ã€ãªã³ãšåå¿ãé¯äœã圢æããéå±ã€ãªã³ã®ãã¬ãŒãå€ïŒã¯ãããŠã¹ã®ã¢ã«ããèªçºé®çã«å¯Ÿãã
ç£å Žã®å¹æãéšåçã«é転ãããããšãããããŸããããã«ã«ã·ãŠã ã€ãªããã©ã¢ã§ããA2 1387ïŒèšè¿°ééãã§ããããããã
A2 3187ïŒCa2+ãªã©ã®2䟡éœã€ãªã³ã«ç¹ç°æ§ã®é«ãã€ãªããã©ã¢ã®ã²ãšã€ïŒã¯ã¢ã«ããã®é®çå¹æã®äœäžãå¢åŒ·ããŸãã(KavaliersïŒ
Ossenkopp, 1986 a) ã
- [å¿åãã]
>>375
æŸæäœåé€ãšæŸæäœã®ããŒã¯å€é掻åã®é䟵襲çæå¶ã®äž¡æ¹ãããŠã¹ã®å€éã®ã¢ã«ããèªçºæ§é®çãæžè¡°ãã(Lakin et al, 1981;
Kavaliers et al, 1983)äžã€ããŠã¹ãšã©ããã®åºåºäŸµå®³å容åå¿ãæžå°ãããããšã瀺ãããŠããããããªããªã€ãç³»ã«å¯Ÿããç£å Ž
ã®æå¶ç圱é¿ã«ã¯ãæŸæäœãšã®çžäºäœçšãå«ãŸããå¯èœæ§ããããŸã(Kavaliers et al, 1983; Bar-OrïŒBrown, 1989)ãããã«ãè¡å
ããã³å
åæ³ã®ç 究ã§ã¯ãæŸæäœãšãªããªã€ãç³»ãšã®çžäºäœçšã瀺åãããŠããŸã(DafnyïŒBurks, 1976; Zatz&Brownstein, 1979;
Geffard et al, 1981; Kavaliers, 1984; Kavaliers et al, 1983; Lowenstein et al, 1984; Lissoni et al, 1986; SandykïŒFisher
, 1989 b; c)ã
- [å¿åãã]
- ãã®æçš¿ã¯åé€ãããŸãã
ä»äºäžã¯iPhoneãèŠå®ãæºåž¯ãiPad, iPod, ã¯ã€ãã¡ã€çã¯é»æºãåãã
ã¢ã«ããã€ãŒã«ã§äºéã«ããŠãæŽã«åãéå±ã ãã§åºæ¥ãŠããå¯é床ãé«ãè»éã®åŒŸäžžã±ãŒã¹(iPadã10åéãããããã®ãµã€ãº)ã«å
¥ãããš
GPSã§ã®å±
å Žæã®äœæ衚瀺ã
çèŽãçæ®ãåçãåç»çã®ããŒã¿æãã®å¿é
ãç¡ãå®å
šã
- [å¿åãã]
>>376
ãªããªã€ãããããã«å¯Ÿããç£å Žã®å¹æã¯ã以äžãå«ãããã€ãã®çç±ã§ããŒãã³ãœã³æ§çç¶ã«ãšã£ãŠèšåºçã«èå³æ·±ããã®ã§ãïŒ
(a) éåå¶åŸ¡ã«äžå¯æ¬ ãªåœ¹å²ãæããç·æ¡äœãšæ·¡èŒçïŒGABAäœåæ§ã®å€§åã®æå°ãã¥ãŒãã³ãå«ããè³ã®ç®è³ªäžæ§é ã®ã²ãšã€ã§å€§è³
åºåºæ žã®äžéšïŒã«ã¯ãæ¯èŒçé«æ¿åºŠã®ãªããšãŒãå容äœãšãšã³ã±ãã¡ãªã³ïŒã¢ã«ããã®ãããªéº»é
ã»é®çäœçšãæã€ãããã (ã¢ãã
é
žãè€æ°åçµåãããã®) ïŒã®äž¡æ¹ãå«ãŸããŠããŸã(Pert et al, 1976; Simantov et al, 1976; Pollard et al, 1978)ïŒ
- [å¿åãã]
>>379
(b) ããŒã¿ãšã³ãã«ãã£ã³ã¯ç·æ¡äœããã®ããŒããã³æŸåºãé»å®³ã(Loh et al, 1976)ãåç©ããã³ããã®è¡æŒ¿ããã©ã¯ãã³æ¿åºŠã
å¢å ãã(Agnoli et al, 1980)ããªããšãŒããããŒããã³æŸåºãé»å®³ããããšã瀺åããŠããŸã(Iwatsubo, 1983);
ïŒcïŒããŒã¿ãšã³ãã«ãã£ã³ãŸãã¯ã¢ã«ããã®æäžã¯ãããŒãã³ãœã³æ§çç¶ã®ç¡¬çŽããã³éåäœäžã«é¡äŒŒã®ã©ããå
ã®ã«ã¿ã¬ãã·ãŒã
ãã³ç¡¬çŽãçã(Wand et al, 1973; Bloom et al, 1976)ããã®ã«ã¿ã¬ãã·ãŒç¶æ
ã¯ãªããšãŒãæ®æè¬ãŸãã¯ããŒããã³äœåè¬ã«ãã£
ãŠé転ãããŸã(Wand et al, 1973)ïŒ
- [å¿åãã]
>>380
(d) ãªããªã€ãããããã®ã¬ãã«ã¯ãããŒãã³ãœã³ç
æ£è
ã®ç·æ¡äœïŒAgid&Javoy-Agid, 1985ïŒããã³ããŒãã³ãœã³æ§ã®éé·é¡ã¢ãã«
ïŒZamir et al, 1984ïŒã§æžå°ããŠããŸãïŒ
(e) CSFãšã³ã±ãã¡ãªã³ã¬ãã«ã¯ãçŸæ£ã®åæ段éã®ããŒãã³ãœã³ç
æ£è
ã§å¢å ããããšãå ±åãããŠããŸã(Pezzoli et al, 1984)ã
ããã«ãCSFã®ããŒã¿ãšã³ãã«ãã£ã³ã®ã¬ãã«ã¯ãæ²»çãããŠããªãããŒãã³ãœã³ç
æ£è
ã§ã¯æžå°ãããšå ±åãããŠããŸã(Nappi et
al, 1985)ïŒ
- [å¿åãã]
æªäŸæ¶æ»
- [å¿åãã]
>>381
(f) å°æ°ã®æ£è
ã«ãããäºåç 究ã«ããããªããšãŒãæ®æè¬ããããœã³ã®æäžã«ããããŒãã³ãœã³ç
ã®æ¯æŠãšç¡¬çŽã軜æžã(Diamond
ïŒBorison, 1978; Vardi et al, 1979; Agnoli et al, 1980; Sandyk, 1985)ãã¬ãããèªçºæ§ãžã¹ãããžã¢ã®éç床ããã³
ããªã³ãªãããæžå°ããïŒTrabucchi et al, 1982; SandykïŒSnider, 1986ïŒããšã瀺ãããŠããŸãããããŠïŒ
(g) ããã¢ã¯ãªããã³ãªã©ã®æããŒãã³ãœã³ç
è¬ã¯ããšã³ã±ãã¡ãªã³å容äœãšã®ã¢ãã¹ããªãã¯çžäºäœçšãéããŠéšåçã«ããŒãã³
ãœã³æ§çç¶ã«æ²»çå¹æãçºæ®ããããšãã§ããŸã(Ogawa et al, 1981; Ogawa&Yamamoto, 1985)ã
- [å¿åãã]
ã¢ã¶ãŒã«ãã=ã¯ã©ããã»ã€ãã³ã®ãã¹ãïŒãããã奜ãã ïŒã®ã²ãããã
ïŒå
šè£žç£ç£ãã»ã€ãã³äŒç»ïŒæ倪åããŒãªã£ïŒå¥³å倧çããã
ïŒå«ãããã¹ããŒã«ãŒïŒãã€ãã«ãŽãæã¡åž°ããæ
å ±åé
ã¯ã©ããã»ã€ãã³ã®ãã¹ãã®åœŒå¥³ïŒæ³
è¯ãã³ã¯ããã¹ãã€ããŒããã芧äžããïŒããã³
- [å¿åãã]
>>355ãéå£ã¹ãã«ã¯ãã¡ãªã®ïŒãå±€åã¯âå¯ãšçµèšããŠããçžè«ããŠã絶察話é²ãŸãªããã ãããå¥ä»¶ã§è¢«å®³å±ãã ãããã©ãåãããç¯äººéãæãŸããã€ããã¯ãªãã£ããããã£ã¡ã§ãããã調ã¹ãŠãããã¡ã«ããããããããã£ããä»ã®æ¥æ¬ã®ãŸãŸã§ã¯ç¡çã ã£ãŠããããã¬ã€ã«ã«ãã®ããããæŸé¡ã ããããéã«çžè«ãããã£ã¡ãç¯äººæ±ããããé¥ããããããæ¬åœã«å¥Žçã¯ããã¬ã€ã ãããã£ã¡ã¯å®æãšã¯çžããããããªãã
- [å¿åãã]
âã©ã³ã¹çµç¹ã®æ¹ã
ããã®æªéã«ã«ãæãå©ã朰ããŠäžããã893å©æš©ã®âãªã³ããã¯èŠããŸãã
- [å¿åãã]
>>385
éå£ã¹ãã«ã£ãŠå€ãªç¥ãæ¹ã ãªwwwwwwww
éã¹ãã§ãããªãïŒ
- [å¿åãã]
>>383
â NALTREXONE ATTENUATES THE ANTIPARKINSONIAN EFFECTS OF PICOTESLA RANGE MAGNETIC FIELDS
ãã³ãã¹ã©ç¯å²ã®ç£çã®åããŒãã³ãœã³ç
å¹æã匱ãããã«ãã¬ããœã³
ãããã£ãŠãç£å Žã¯ãªããªã€ãããããã®æŽ»æ§ã«åœ±é¿ãããããããŒãã³ãœã³æ§çç¶ã«ãããç£å Žã®æçãªå¹æã¯ãã¡ã©ããã³ã«
å ããŠãå
å æ§ãªããªã€ãããããã®åªä»ãå«ãå¯èœæ§ããããŸãããã®åé¡ãããã«æ¢ãããããã³ãã¹ã©ç¯å²ã®ç£å Žã§æ²»çãå
ããåŸã«çç¶ã®æ¹åã瀺ããããŒãã³ãœã³ç
æ£è
ã®ãªããšãŒãå容äœæ®æè¬ãã«ãã¬ããœã³ã®å¹æã調æ»ããŸããã
- [å¿åãã]
>>388
çäŸå ±å
ããã®37æ³ã®ç·æ§ã¯ã1986幎ã«30æ³ã§ããŒãã³ãœã³æ§çç¶ãšèšºæãããŸããã圌ã®æåã®çç¶ã¯1983幎ãå°åçïŒææžãæåã®ç®å°å
ïŒã«ããææžãã®ããã¡ãªããšé¢é£ããæç²åŽæ§ïŒç²ããããïŒã身äœã®å³åŽã®ããã°ããçºçäžå
šãåããŠçµéšããæã«çŸããŸããã
- [å¿åãã]
>>389
1986幎ã圌ã®å³è¶³ãåŒãããããŠããããšã«æ°ä»ãã以åã®èã®è² å·ã«é¢ä¿ããŠãããšèšãããŸãããããããæ°ãµæåŸã圌ã¯é¡ã®
ç¡è¡šæ
çãå³æã®å®éææ¯æŠããã³ããã»ã©ã§ã¯ãªããå³è¶³ã®çç¶ãåãããšãã«ããŒãã³ãœã³æ§çç¶ãšèšºæãããŸããã圌ã¯æ£åžž
ã ã£ãè³ã®ç£æ°å
±é³Žç»åïŒMRIïŒã¹ãã£ã³ãåããŸãããåæ§ã«ãè¡æŒ¿é
ããã³ã»ã«ããã©ã¹ãã³ãå«ãåºç¯ãªå®éšå®€èª¿æ»ããã³éé
å±ã¹ã¯ãªãŒãã³ã°ã¯ç®ç«ãã¡ãŸããã§ããã1986幎ã«ã¡ã·ã«é
žãã³ãºãããã³(CogentinR 1.5 mg/d)ã«ããæããŒãã³ãœã³ç
æ²»çã
éå§ãã1987幎ã«æ²»çå
ã§ã»ã¬ã®ãªã³(10 mg/d)ãè¿œå ãããŸããã1990幎ã«ã圌ã¯ãã©ã³ã¹ãšæ©è¡ã®å°é£ãå¢ããããšã«æ°ä»ããåŸã
ã¡ã·ã«é
žãã«ãŽãªã(PermaxR; 3 mg/d)ã«ããæ²»çãéå§ããŸããã
- [å¿åãã]
>>390
è©äŸ¡æã«ã圌ã¯ã¡ã·ã«é
žãã«ãŽãªãïŒ4 mg /æ¥ïŒãã»ã¬ã®ãªã³ïŒ10 mg /æ¥ïŒãã¡ã·ã«é
žãã³ãºãããã³ïŒ1.5 mg /æ¥ïŒããã«ãªã
ã»ãã³ïŒéæ¥20 mgïŒããã¿ãã³EïŒ3000 IU /æ¥ïŒãããŒã¿ã«ããã³ïŒ250-1000åäœ/æ¥ïŒããã¿ãã³CïŒ2-4 g /æ¥ïŒãã»ãªããŠã
ïŒ50 mcg /æ¥ïŒãããã³ããã«ã®ã³ïŒ6 mg /æ¥ïŒãæçšããŠããŸããã圌ã®éå»ã®ç
æŽã¯ãçŽ16æ³ã§å§ãŸã£ã粟ç¥çãã€çç¶ã«ã€ã
ãŠé¡èã§ãããå粟ç¥è¬ãŸãã¯ç£æ¥æ¯çŽ ãžã®æŽé²ã®å±¥æŽã¯ãããŸããã§ããã圌ã®å®¶ææŽã¯ã䞡芪ã®ãã€ç
ãšæ
¢æ§ã¢ã«ã³ãŒã«äžæ¯ã§
é¡èã§ããã
- [å¿åãã]
>>391
æ€æ»ã®çµæã圌ã¯é¡ãšé¡ã®èæŒïŒéæ¥æåŸã«éŒ»ãé éšã«ã¿ãããæ²¹æ§èæŒãšãããµãããšäžè¬ã«ãã¶ä¹Ÿæ§èæŒãšã«å€§å¥ãããç®èè
º
ã®åæ³ãéå°ãªç¶æ
ïŒã䌎ãé¡ã®è¡šæ
ã®æžå°ãšèªçºçãªç¬ãã®æžå°ã瀺ããŸãã(8å/å)ã圌ã®ã¹ããŒãã¯çºçäžå
šïŒäœé³ïŒã§ãææ
ã©ãããããããããã«æ§é³é害ã§ãããèŠç©ºéèœåããã¹ãããããã«ã圌ã¯å³åçã®æ©èœé害ã瀺åãããèŠèŠæ§ç¯æ©èœé害ã®
蚌æ ãæã€åçŽåããããã¶ã€ã³ã瀺ã家ãæãããã«æ瀺ãããŸãã(Lezak, 1985)(å³1)ãéåæ€æ»ã§ã¯è
ã䌞ã°ããšå³æã«è»œã
æ¯è»æ§ç¡¬çŽ(ããŒãã³ãœã³ç
æ£è
çã®çåºçž®ã§èŠãããæç¶çãªæµææ§)ããããå³æã«åŸ®åãããããšã瀺ãããŸãããæ€
åããã®
ç«ã¡äžããã¯ãããã«é
ããæ©è¡äžã«åœŒã¯å³è¶³ã軜ãåŒããããŸãããåŸãããåªããåŒã£åŒµããšãã©ã³ã¹ã厩ãã姿å¢åå°ãæãªã
ããŸããã
- [å¿åãã]
é»ç£æ³¢è¢«å®³è
ã§ãã
é«ç¥äžç©ºã«èªç©ºèªè¡éãæ¥ãŠãããŠããŸãã
é£è¡é²ãåºããŠãããŠããŸãã
被害è
ã®æ¹ã
ãå©ããæ±ããŠäžããã
- [å¿åãã]
ã«ã«ãä¿¡è
ã«äœå¹Žãäœå¹Žãä»ãçºãããŠãåå
æäžèšèã®æ»æã
ãããŠããããäœãå¿ãäŒãæããªã(å°±å¯äžã§ããã倢ã«çŸããŠæ»æããŠæ¥ã)
ã«ã«ãä¿¡è
ã®æ¹ã¯ããã€ã§ããã€ãã³ã·ã§ã³ã§ç²ãç¥ãã
ãã£ã¡ã®äœèª¿ãæªãããããå¿ãç²åŒããŠãæã«ã§ãæ
ã容赊ãªã
èšèã®éãæ¯ãã£ãŠæ¥ã
ãããã§ãæè¿ã§ã¯å¿ãäœããããã
ããã«æ¹å€çãªäºãæžã蟌ã¿ãããšãä»åºŠã¯ãè£å€ããåŒè·å£«ãããã£ãŠè
ããŠæ¥ã
å€åºå
ã«ãçŸããŠãæªå£èšããªãããè£å€ããåŒè·å£«ãããã£ãŠä»ããããŠç¬ã£ãŠã
æè¿ã§ã¯ãç¡é¢ä¿ãªã®ã«ãæå£ã®éå¶è²»ããããšãŸã§èšãå§ããŠã
- [å¿åãã]
>>392
â NALTREXONE ATTENUATES THE ANTIPARKINSONIAN EFFECTS OF PICOTESLA RANGE MAGNETIC FIELDS
ãã³ãã¹ã©ç¯å²ã®ç£çã®åããŒãã³ãœã³ç
å¹æã匱ãããã«ãã¬ããœã³
ç£å Žã«ããæ²»ç
ãç£å Žã«ããæ²»çã«ã€ããŠã€ã³ãã©ãŒã ãã³ã³ã»ã³ããåŸãåŸãæ£è
ã¯æåãç£æ°çã«é®èœãããŠããªãéãã§äººå·¥çã«ç
§æããã
éšå±ã§30åéã®ç䌌ã®ïŒãã©ã»ãïŒæ²»çãåããŸãããåŠçœ®äžãæ£è
ã®ç®ã¯ç®é ãã§èŠãé ãããŸãããç£æ°è£
眮(Sandyk
Electromagnetic Stimulator)ïŒäžèšåç
§ïŒã®ã³ã€ã«ã¯ãè£
眮ã®ã¹ã€ããããªã³ã«ããã«é ç¹äžã«é
眮ãããŸãããåŠçœ®äžãæ£è
ã¯
åœã®ç£å ŽãåããŠããããšã«æ°ã¥ããŸããã§ããã
- [å¿åãã]
>>395
ãã©ã»ãæ²»çã®çµäºçŽåŸã«æ£è
ã¯ããŒãã³ãœã³ç
ã®çç¶ã®å€åã«ã€ããŠæ€æ»ãããåŒãç¶ããŠæç»äœæ¥ãç¹°ãè¿ãããæ瀺ãããŸã
ãïŒå³2ïŒããã®åŸãç£æ°åºæ¿ã30åéå ããŸãããç£å Žã¯ã16åã®ã³ã€ã«ãå«ãå€éšç£æ°èª¿æ»åšãä»ããŠé ç®ã«é©çšãããŸããã
åã³ã€ã«ã®é¢ç©ã¯3.14 cm^2ã§ããããããã®ã³ã€ã«ã¯ãã³ã€ã«ã®è»žã«å¹³è¡ãªåç·ãæã€ç£çãçæããŸãããã³ã€ã«ã®äœçœ®ã¯ãç£å Ž
å
šäœãåäžã«ãªããããªãã®ã§ãããçæãããç£å Žã¯ã0ã10 KHzã®åšæ³¢æ°ç¯å²ãš0ã60 microTeslaã®ç¯å²ã®åŒ·åºŠã®äº€æµã§ããã
ãã®å Žåãç£å Žã®åŒ·åºŠã¯7.5ãã³ãã¹ã©ã§ãåšæ³¢æ°ã¯5 Hzã§ãã
- [å¿åãã]
>>0
è¬ãè¬ç© å¬ç
æèçèŽ é³å£°éä¿¡
å¬ç ã䜿ãã°ç°¡åã«åºæ¥ãããªãã¯ã§ãã
- [å¿åãã]
ãŸããïŒãã£ãšé©ãé ããã€ããªãã£ãŒä»£çå·¥äœ
- [å¿åãã]
æŽè³ïŒ
- [å¿åãã]
ãããåŠäŒã«ç Žé²æ³ãé©çšããã殺人éå£ãä¿¡è
倧å¢
- [å¿åãã]
éå£ã¹ããŒã«ãŒã«å æ
ãã人éã¯ãå°çã«èœã¡ãã
- [å¿åãã]
>>401
æ瀺ããŠã人éãèœã¡ããã ããç¥ããªããã¡ã«éæ¥çã«å©çšãããŠãã ãã®è¢«å®³è
ããããããäžæŠã«ã¯èšããªãããç掻ä¿è·å絊è
ã«ã¯ããã被害è
ãå€ãã®ã«ãå絊è
ãå 害䞻äœã ãã¿ããã«å°è±¡ä»ããäºä»¶ãšãäºæ
ã蚎ãã人ã®æ
å ±ããã£ããèŠæ³šæã ãããã ã®äžå±€æ瀺ãããã¯ãŒã¯ã«èžããããŠãã ãã ãããã
- [å¿åãã]
>>402
ããããããšã°ããã¯èšããªã
å 害è¡çºã«å æ
ãã人éãã被害è
ã®èº«è¿ãªäººéã«ãŸã§æªåœ±é¿ãåã¶
å€ãªç
æ°ã«çœ¹ã£ããã倧ã±ã¬ããã
- [å¿åãã]
|
|